CRISPR Therapeutics (CRSP) revenue

Revenue · fiscal 2024
$35.00M

CRISPR Therapeutics (CRSP) reported revenue of $35.00M in fiscal 2024 (the year ended December 31, 2024). That is 90.5% lower than the $370.00M of fiscal 2023. Figures as of 18 Nov 2026, 11:51 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Revenue, fiscal 2024
$35.00M
Change on fiscal 2023
−90.5%
Growth, 5 years
−34.5% a year
Highest on record
$914.96Mfiscal 2021
Lowest on record
$247.00Kfiscal 2015
Fiscal years on record
102015–2024

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

CRISPR Therapeutics revenue, in more detail

Over the five fiscal years to 2024 revenue shrank at a compound 34.5% a year. Across the 10 fiscal years on record (2015–2024), the highest was $914.96M in fiscal 2021 and the lowest $247.00K in fiscal 2015.

History · 10 fiscal years

Revenue by fiscal year

CRISPR Therapeutics revenue, year by year

CRISPR Therapeutics (CRSP) revenue by fiscal year
Fiscal yearRevenueChangeYear ended
2024$35.00M 90.5% down
2023$370.00M 84,762.4% up
2022$436.00K 100.0% down
2021$914.96M 127,154.9% up
2020$719.00K 99.8% down
2019$289.59M 9,169.8% up
2018$3.12M 92.4% down
2017$41.00M 693.9% up
2016$5.16M 1,990.7% up
2015$247.00K—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Revenue is everything the company billed its customers over the fiscal year — the top line of its income statement.

How to read it

Steady growth in revenue is the raw material for everything else; a fall means the company is selling less or charging less.

Revenue at health care companies of similar size

Revenue of CRISPR Therapeutics and comparable companies
CompanyRevenueFiscal year
MiniMed Group MMED$3.10B2026
Adaptive Biotechnologies ADPT$276.98M2025
Heartflow HTFL$176.03M2025
CRISPR Therapeutics CRSP$35.00M2024
Travere Therapeutics TVTX$490.73M2025
Option Care Health OPCH$5.65B2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on CRSP

CRISPR Therapeutics, figure by figure

CRISPR Therapeutics (CRSP) overview: price, valuation and scorecardAll health care companies by market value

CRISPR Therapeutics revenue: questions and answers

What is CRISPR Therapeutics's revenue?

CRISPR Therapeutics (CRSP) reported revenue of $35.00M in fiscal 2024 (the year ended December 31, 2024). That is 90.5% lower than the $370.00M of fiscal 2023.

What is the growth rate of CRISPR Therapeutics's revenue?

Over the five fiscal years to 2024 revenue shrank at a compound 34.5% a year.

What are the highest and lowest revenue figures on record for CRISPR Therapeutics?

Across the 10 fiscal years on record (2015–2024), the highest was $914.96M in fiscal 2021 and the lowest $247.00K in fiscal 2015.

How is CRISPR Therapeutics's revenue calculated?

Revenue is everything the company billed its customers over the fiscal year — the top line of its income statement. For CRISPR Therapeutics it is on record here for 10 fiscal years, 2015 to 2024.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “CRISPR Therapeutics (CRSP) revenue”, data as of 18 November 2026. https://funkfolio.com/stock/CRSP/revenue

Underlying data: the company's filings with the SEC and Yahoo Finance.